Spark Therapeutics Tops $1 Billion in Financing with Latest Public Offering

September 1, 2017: By Joan McKenna

SparkSpark Therapeutics has raised about $380.4 million in a public offering of 5.3 million shares of common stock, the Philadelphia gene therapy company announced Aug. 9.

The company says it has now secured $1 billion in total financing. Spark was founded in March 2013.

It is developing gene therapies that address inherited retinal diseases, neurodegenerative diseases, and diseases that can be addressed by targeting the liver, such as hemophilia.

Spark’s most advanced candidate, with the proposed trade name Luxturna (voretigene neparvovec), is currently under priority review with the US FDA for the treatment of biallelic RPE65-mediated inherited retinal disease. The company has filed for marketing approval with the EMA for the treatment of vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations. Luxturna has received breakthrough therapy and orphan status from the FDA, as well as orphan status from the EMA. Spark’s pipeline also includes SPK-7001 in an ongoing Phase I/II clinical trial for choroideremia.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Cowen and Company, LLC, acted as book-running managers for the offering.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023